We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov Menu

Bevacizumab Effect on Blood Velocity

This study has been completed.
ClinicalTrials.gov Identifier:
First Posted: February 17, 2011
Last Update Posted: February 17, 2011
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
Optical Imaging, Ltd.
Retinal blood flow velocity is affected by Bevacizump intravitreal injection. This effect is correlated to treatment success.

Choroidal Neovascularization

Study Type: Observational
Study Design: Observational Model: Case-Only
Time Perspective: Prospective
Official Title: The Effect of Intravitreal Bevacizumab (Avastin) Injection on Retinal Blood-Flow Velocity in Patients With Choroidal Neovascularization

Resource links provided by NLM:

Further study details as provided by Optical Imaging, Ltd.:

Primary Outcome Measures:
  • Blood flow velocity change [ Time Frame: 1 day following injection ]

Enrollment: 12
Study Start Date: January 2008
Study Completion Date: June 2008
Primary Completion Date: June 2008 (Final data collection date for primary outcome measure)
Detailed Description:
The purpose of the study was to carry out a pilot study on the short-term effect of intravitreal Bevacizumab (Avastin) injection on retinal blood-flow velocity and test whether the short-term haemodynamic changes could predict the longer term clinical result of the treatment.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   Child, Adult, Senior
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Patients with choroidal neovascularization (CNV)

Inclusion Criteria:

  • Patients with CNV receiving Bevacizumab intravitreal injection

Exclusion Criteria:

  • Candidates in whom the retina could not be seen clearly because of media opacity or a poorly dilating pupil
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01298440

Tel aviv sourasky medical center
Tel aviv, Israel, 64239
Sponsors and Collaborators
Optical Imaging, Ltd.
Principal Investigator: Adiel Barak, MD Tel aviv university Sackler school of medicine
  More Information

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Optical Imaging, Ltd
ClinicalTrials.gov Identifier: NCT01298440     History of Changes
Other Study ID Numbers: AvastinRFI
First Submitted: February 16, 2011
First Posted: February 17, 2011
Last Update Posted: February 17, 2011
Last Verified: February 2011

Additional relevant MeSH terms:
Neovascularization, Pathologic
Choroidal Neovascularization
Pathologic Processes
Choroid Diseases
Uveal Diseases
Eye Diseases
Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Growth Substances
Physiological Effects of Drugs
Growth Inhibitors
Antineoplastic Agents